KIO-301's photoswitch mechanism targets vision restoration in advanced RP; Phase 2 ABACUS-2 data will determine whether early signals replicate at scale

Kiora Pharmaceuticals is a clinical-stage company developing a small-molecule drug to restore vision in patients with advanced retinitis pigmentosa who have lost functional photoreceptors; the drug is not yet approved.

KIO-301 is a small-molecule photoswitch in Phase 2 targeting vision restoration in patients with advanced retinitis pigmentosa who have lost functional photoreceptors. The thesis resolves on whether ABACUS-2 Phase 2 data confirm functional vision gains seen in ABACUS-1 at an efficacious and tolerable dose. Gene therapy competitors including Ocugen's OCU400 and MeiraGTx's AAV-based RP programs could displace KIO-301 if they demonstrate durable, mutation-agnostic efficacy ahead of this readout.